CDK4 and breast carcinoma: The commercially available and FDA-approved CDK4/6 inhibitors Palbociclib, Ribociclib, and Abemaciclib have different inhibition profiles against CDK isoforms resulting in diverse phenotypic effects on ER+ breast cancer [19–21].